ClinicalTrials.gg
CompletedNCT00875979Updated Dec 24, 2013Results posted

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

A Phase 1/2 interventional study of Trastuzumab emtansine [Kadcyla] 3.0 mg/kg and Trastuzumab emtansine [Kadcyla] 3.6 mg/kg in Metastatic Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-24.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms — 11 open to participants now, 16 under way, 2 of them phase 3. Ado-Trastuzumab Emtansine · Breast Neoplasms.

Enrollment
35th of 56
67 · median 103
Started
2009
with 5 others
Phase 1/2
4 of 56
none open now
Registered
5th of 56
by date
Lead sponsor
18 of 56
Hoffmann-La Roche

Among the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, this one is the 35th largest by enrollment, is one of 6 that started in 2009, is one of 4 in phase 1/2, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About Ado-Trastuzumab Emtansine

Ado-Trastuzumab Emtansine: first FDA approval 2013 (KADCYLA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing Ado-Trastuzumab Emtansine in Breast Neoplasms, or all of them as a file.
02

Study summary

This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by intravenous (IV) infusion in combination with pertuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced or metastatic breast cancer who had previously received trastuzumab.

Read the detailed description

There were 2 phases in the study, a Dose Escalation phase (Phase 1b) and a Dose Expansion phase (Phase 2a). In the Dose Escalation phase, 3 patients were enrolled at the first dose level (3.0 mg/kg trastuzumab emtansine) and and 6 patients were enrolled at the second dose level (3.6 mg/kg trastuzumab emtansine). An additional 58 patients were enrolled at the 3.6 mg/kg trastuzumab emtansine dose level in the Dose Expansion phase (Phase 2a) of the study.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • MBC
  • Breast Cancer
  • HER2+
  • HER2+ breast cancer
  • HER2 positive breast cancer
  • herceptin
  • Trastuzumab emtansine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented human epidermal growth factor receptor 2 ()-positive locally advanced or breast cancer.
  • Tumor tissue blocks or 15-20 unstained tissue slides for confirmatory central laboratory HER2 status testing and other exploratory assessments.
  • Prior trastuzumab in any .
  • No prior trastuzumab emtansine (T-DM1) or pertuzumab therapy.
  • .
  • For women of , agreement to use an effective form of and to continue its use for the duration of the study.
  • ≥ 90 days.

Exclusion criteria

Exclusion Criteria:

  • Less than 21 days since the last anti-tumor therapy, including chemotherapy, biologic, experimental, immune, hormonal, or radiotherapy for the treatment of breast cancer, with the following exceptions: Hormone-replacement therapy or oral ; palliative radiation therapy involving ≤ 25% of marrow-bearing bone if administered ≥ 14 days prior to first study treatment.
  • History of intolerance or to trastuzumab and/or adverse events related to trastuzumab that resulted in trastuzumab being permanently discontinued.
  • Peripheral neuropathy of Grade ≥ 2.
  • History of cardiac dysfunction.
  • Current severe, uncontrolled systemic disease, eg, clinically significant cardiovascular, pulmonary, or metabolic disease.
  • that are untreated, progressive, or have required any type of therapy to control symptoms from brain metastases within 60 days of the first study treatment.
  • History of other within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Trastuzumab emtansine 3.0 mg/kg + pertuzumab 420 mg

    Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.

    Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg · Drug: Pertuzumab 420 mg

  • Experimental
    Trastuzumab emtansine 3.6 mg/kg + pertuzumab 420 mg

    Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.

    Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg · Drug: Pertuzumab 420 mg

Interventions

  • DrugTrastuzumab emtansine [Kadcyla] 3.0 mg/kg

    Drug page: Ado-Trastuzumab Emtansine

    Trastuzumab emtansine was provided as a single-use lyophilized formulation.

    Also known as: trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1

  • DrugTrastuzumab emtansine [Kadcyla] 3.6 mg/kg

    Drug page: Ado-Trastuzumab Emtansine

    Trastuzumab emtansine was provided as a single-use lyophilized formulation.

    Also known as: trastuzumab-DM1, trastuzumab-MCC-DM1, T-DM1

  • Pertuzumab was provided as a single-use formulation.

    Also known as: Perjeta

06

What researchers measure

Primary outcomes

  1. Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)

    A patient had an objective response if they had a complete response or a partial response on 2 consecutive occasions ≥ 4 weeks apart. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.

    Time frame: Baseline through the end of the study (up to 2 years 3 months)

Secondary outcomes

  1. Duration of Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)

    Duration of objective response was defined as the time from initial response to disease progression (PD) or death from any cause. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.

    Time frame: Baseline through the end of the study (up to 2 years 3 months)

  2. Progression-free Survival Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)

    Progression-free survival was defined as the time from randomization to first documented disease progression (PD) or death due to any cause within 30 days of the last treatment, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.

    Time frame: Baseline through the end of the study (up to 2 years 3 months)

07

Results

Posted Jul 18, 2013

Participant flow

There were 2 phases in the study, a Dose Escalation phase (Phase 1b) and a Dose Expansion phase (Phase 2a).

Dose Escalation Phase - 3.0 mg/kg
Participant flow — Dose Escalation Phase - 3.0 mg/kg
MilestoneTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
Started30
Completed00
Not completed30
Withdrew: Disease progression10
Withdrew: Physician decision10
Withdrew: Patient/legal guardian decision10
Dose Escalation Phase - 3.6 mg/kg
Participant flow — Dose Escalation Phase - 3.6 mg/kg
MilestoneTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
Started06
Completed00
Not completed06
Withdrew: Disease progression06
Dose Expansion Phase - 3.6 mg/kg
Participant flow — Dose Expansion Phase - 3.6 mg/kg
MilestoneTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
Started058
Completed011
Not completed047
Withdrew: Disease progression037
Withdrew: Physician decision03
Withdrew: Patient/legal guardian decision03
Withdrew: Started non-protocol anti-cancer therapy03
Withdrew: Death01

Outcome measures

PrimaryObjective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)

A patient had an objective response if they had a complete response or a partial response on 2 consecutive occasions ≥ 4 weeks apart. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.

Time frame:
Baseline through the end of the study (up to 2 years 3 months)
Reported as:
Number · Percentage of patients
Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Percentage of patientsTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)66.7 (13.5 to 98.3)40.6 (28.5 to 53.6)
SecondaryDuration of Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)

Duration of objective response was defined as the time from initial response to disease progression (PD) or death from any cause. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.

Time frame:
Baseline through the end of the study (up to 2 years 3 months)
Reported as:
Median · Months
Duration of Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
MonthsTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
Duration of Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)8.6 (NA to NA)13.9 (6.93 to NA)
SecondaryProgression-free Survival Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)

Progression-free survival was defined as the time from randomization to first documented disease progression (PD) or death due to any cause within 30 days of the last treatment, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.

Time frame:
Baseline through the end of the study (up to 2 years 3 months)
Reported as:
Median · Months
Progression-free Survival Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
MonthsTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
Progression-free Survival Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)13.8 (NA to NA)6.6 (4.21 to 9.46)

Adverse events

Collected over From informed consent until treatment start (T), serious adverse events (SAE) related to protocol procedures were reported. From the start up to 30 days after the end of T, all AEs and SAEs were reported. Thereafter, only T-related SAEs were reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mg—0/3 (0%)3/3 (100%)
Trastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg—22/64 (34.4%)64/64 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
CellulitisInfections and infestations0/33/64
PneumoniaInfections and infestations0/33/64
Pleural effusionRespiratory, thoracic and mediastinal disorders0/33/64
DyspnoeaRespiratory, thoracic and mediastinal disorders0/33/64
NauseaGastrointestinal disorders0/32/64
VomitingGastrointestinal disorders0/32/64
Abdominal painGastrointestinal disorders0/32/64
Pericardial effusionCardiac disorders0/31/64
TachycardiaCardiac disorders0/31/64
ColitisGastrointestinal disorders0/31/64
Most frequent other events
Showing 10 of 61
Most frequent other events
EventTrastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mg
FatigueGeneral disorders3/339/64
AnaemiaBlood and lymphatic system disorders2/37/64
NauseaGastrointestinal disorders2/332/64
ChillsGeneral disorders2/320/64
Decreased appetiteMetabolism and nutrition disorders2/322/64
DysgeusiaNervous system disorders2/316/64
HeadacheNervous system disorders2/316/64
DyspnoeaRespiratory, thoracic and mediastinal disorders2/314/64
EpistaxisRespiratory, thoracic and mediastinal disorders2/316/64
DiarrhoeaGastrointestinal disorders1/325/64

Baseline characteristics

Treated population: All patients who received at least 1 dose of study drug and had at least 1 follow-up tumor assessment.

Age, Continuous
Age, Continuous(years)Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mgTotal
Mean53.3 ± 1.552.7 ± 10.852.7 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Emtansine 3.0 mg/kg + Pertuzumab 420 mgTrastuzumab Emtansine 3.6 mg/kg + Pertuzumab 420 mgTotal
Female36366
Male011
08

Study locations

20 sites
  • Boca Raton, Florida 33428, United States
  • Deerfield Beach, Florida 33442, United States
  • Maywood, Illinois 60153, United States
  • Indianapolis, Indiana 46202, United States
  • Wichita, Kansas 67214, United States
  • Rockville, Maryland 20850-3348, United States
  • Chapel Hill, North Carolina 27514, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Philadelphia, Pennsylvania 19111, United States
  • Nashville, Tennessee 37203, United States
  • Bruxelles, 1000, Belgium
  • Vancouver, British Columbia V5Z 1H5, Canada
  • Montreal, Quebec H3A 1A1, Canada
  • Paris, 75248, France
  • Villejuif, 94805, France
  • Köln, 50924, Germany
  • Aviano, 33081, Italy
  • Milano, 20133, Italy
  • Barcelona, 08035, Spain
  • Valencia, 46010, Spain
09

References and documents

Publications

  • Miller KD, Dieras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014 May 10;32(14):1437-44. doi: 10.1200/JCO.2013.52.6590. Epub 2014 Apr 14. PubMed 24733796 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2009
First posted
Apr 6, 2009
Start
May 2009
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Jul 18, 2013
Last update
Dec 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00875979
Lead sponsor
Hoffmann-La Roche
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Apr 6, 2009
Start date
May 2009
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Jul 18, 2013
Last update
Dec 24, 2013

Study contacts

Elaine K. Wong, M.Sc., M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ado-Trastuzumab Emtansine · Pertuzumab

Start the discussion